Browse the evidence

Single-dose AAV-mediated liver-specific FGF21 gene therapy reverses diet-induced obesity, hepatic steatosis, and insulin resistance in mice through sustained elevation of circulating FGF21 and increased energy expenditure.

This research suggests that a single injection of a viral vector delivering the FGF21 gene to the liver can sustainably reverse obesity and insulin resistance in mice by boosting energy expenditure. While promising, this is preclinical data; human applications are not yet established.

Post-hoc statistical calibration of self-reported data using biomarkers can correct for underreporting, though it often results in small effect sizes for disease outcomes.

If you are reading research on diet and disease, check if they used biomarker calibration. Uncalibrated self-report studies may show misleading inverse relationships (e.g., claiming sugar protects against diabetes).

Menopausal hormone therapy (MHT) using estrogens delays the onset of type 2 diabetes in postmenopausal women, primarily by improving insulin sensitivity and glucose effectiveness, though it is not FDA-approved for this indication due to risk-benefit complexity.

If you are postmenopausal and suffering from symptoms, MHT may help prevent type 2 diabetes by improving how your body handles insulin and glucose. However, it is not prescribed solely for diabetes prevention due to other health risks. Discuss with your doctor if the benefits for your specific symptoms outweigh the risks, especially if you are at higher risk for diabetes.

Metformin reduces hepatic glucose production primarily by inhibiting fructose-1,6-bisphosphatase (FBP1) via AMP-mediated allosteric inhibition, rather than solely through AMPK activation.

Metformin lowers blood sugar partly by directly inhibiting an enzyme (FBP1) in the liver that makes glucose, triggered by changes in cellular energy (AMP). This happens alongside its known effects on AMPK. For patients, this means metformin is effective through multiple pathways, which may explain its broad utility in type 2 diabetes management.

Inhibition of mTORC1 activity is a necessary physiological trigger for initiating autophagy during nutrient deprivation, which recycles cellular components to sustain blood glucose and amino acid levels.

Fasting works by turning off the 'growth' signal (mTORC1), which unlocks the body's internal recycling system (autophagy). This system breaks down old cellular parts to create glucose and amino acids, keeping you alive and healthy during food scarcity. You cannot have this benefit if your body is constantly in 'growth mode' due to constant eating.

Enhancing autophagy through genetic or pharmacological means improves glucose tolerance, insulin sensitivity, and resistance to obesity in high-fat diet models.

Boosting your body's natural cleanup processes (autophagy) can help you stay lean and sensitive to insulin, even if you eat a high-fat diet. This suggests that maintaining cellular health through fasting or exercise is as important as the food you eat.

In tertiary-care diabetic populations, comprehensive management of glycemic, lipid, and blood pressure targets (ABC control) remains suboptimal, with only 20.2% of patients achieving all preset control goals despite high medication availability.

For patients managing diabetes, simply having access to medication is not enough to guarantee health outcomes. This data suggests that achieving comprehensive control (blood sugar, lipids, and blood pressure) is difficult, with only 1 in 5 patients succeeding in a high-resource setting. Focus on the 'why' behind uncontrolled numbers, as medication availability alone does not solve the metabolic burden.

Chronic vascular complications, including retinopathy, nephropathy, neuropathy, and ischemic heart disease, are highly prevalent in diabetic populations, with over half of patients exhibiting at least one complication.

More than half of diabetic patients in this study had at least one chronic complication, such as eye, kidney, nerve, or heart issues. This highlights the critical importance of regular screening for complications, even if you feel healthy, as damage can be silent.

Aerobic exercise does not significantly improve memory or executive function scores in early Alzheimer's disease compared to stretching and toning.

Do not expect aerobic exercise to directly reverse memory loss or improve executive function scores in early Alzheimer's. The primary benefit observed in this study was the maintenance of functional ability (ability to perform daily tasks). Exercise should be prescribed for functional preservation rather than cognitive enhancement.

Aging causes a redistribution of lipids from subcutaneous to visceral adipose tissue, leading to ectopic lipid storage, insulin resistance, and chronic low-grade systemic inflammation.

As you age, your body naturally shifts fat storage from under the skin to around your organs, which increases health risks. This shift is driven by hormonal changes and reduced activity of brown fat. While you can't stop aging, you can counteract these effects through regular exercise, weight management, and potentially medical interventions that improve insulin sensitivity, helping to maintain metabolic health and quality of life.

Declining brown adipose tissue (BAT) activity with age contributes to reduced energy expenditure and increased obesity risk, mediated by reduced sympathetic output and increased FOXA3 transcription factor.

Brown fat, which burns calories to generate heat, becomes less active as you age. This is partly due to reduced nerve signals and changes in gene expression. While you cannot easily reverse this biological change, maintaining physical activity may help stimulate remaining brown fat function.

Aging is associated with an increase in pro-inflammatory adipokines and a decline in anti-inflammatory adipokines, contributing to a chronic state of low-grade systemic inflammation known as 'inflammaging'.

As you age, your fat cells release more inflammatory signals and fewer protective ones, leading to chronic low-grade inflammation. This 'inflammaging' increases the risk of diseases like diabetes and heart disease. Managing weight and staying active can help modulate these inflammatory signals.

Mitochondrial dysfunction is a necessary driver of the Senescence-Associated Secretory Phenotype (SASP), as evidenced by the elimination of SASP in cells devoid of mitochondria, while irreversible cell cycle arrest persists.

Aging and age-related inflammation are driven by dysfunctional mitochondria producing the SASP. Interventions that target mitochondrial health (e.g., senolytics, senostatics like rapamycin or metformin) may reduce this inflammatory burden. Focus on strategies that support mitochondrial quality control, such as exercise and metabolic health, rather than just energy output.

Cognitive engagement and mental stimulation build 'brain and cognitive reserve,' which delays the clinical manifestation of dementia and cognitive decline by increasing neural efficiency and structural resilience.

Actively engage in mentally stimulating activities such as learning a new language, playing musical instruments, solving puzzles, or participating in discussion groups. These activities build cognitive reserve, which helps delay the onset of dementia symptoms.

Metabolic syndrome (MetS) is independently associated with a higher risk of major cardiovascular events, cardiovascular mortality, and all-cause mortality, advancing the onset of these risks by approximately 3.2 years.

Having metabolic syndrome significantly increases your risk of heart attack, stroke, and early death, advancing the onset of these risks by over 3 years. However, managing individual components like high blood pressure, high triglycerides, or low HDL cholesterol is just as effective for risk reduction as treating the syndrome as a whole unit. Focus on controlling these specific metrics.

Metabolic syndrome is NOT associated with a higher risk of myocardial infarction or stroke, although individual components like elevated blood pressure, reduced HDL, and elevated triglycerides are.

Having metabolic syndrome does not necessarily increase your risk of heart attack or stroke, but managing individual components like high blood pressure, low HDL cholesterol, and high triglycerides does reduce this risk. Focus on controlling these specific markers.

Elevated tissue levels of specific ceramide species (C16:0 and C18:0) directly cause insulin resistance and metabolic dysfunction by inhibiting Akt/PKB signaling and mitochondrial efficiency.

High levels of specific fats called ceramides (C16:0 and C18:0) block your body's ability to use insulin, leading to high blood sugar and metabolic disease. While not all fats are bad, these specific ones are key drivers of insulin resistance. Managing overall metabolic health involves addressing these specific lipid accumulations, often through lifestyle changes that improve insulin sensitivity.

Colonic SCFA mixtures attenuate whole-body lipolysis, indicated by decreased fasting free glycerol concentrations.

SCFAs may help reduce the release of fatty acids from fat cells (lipolysis). While this might sound counterintuitive for weight loss, it can help prevent fat from accumulating in the liver and muscles, improving insulin sensitivity. Focus on fiber intake to support this process.

Increasing long-chain omega-3 intake has little or no effect on the risk of developing type 2 diabetes or on glucose metabolism markers (HbA1c, fasting glucose, insulin, HOMA-IR).

If you are taking omega-3 supplements hoping to lower your blood sugar or prevent diabetes, this review suggests you are unlikely to see those specific benefits. The evidence shows no significant change in diabetes risk or glucose levels. Continue taking them if you like for general health, but do not rely on them for diabetes management.

Transfeminine hormone therapy (estrogen + antiandrogens) induces feminizing physical changes including breast development, fat redistribution, and reduced body/facial hair, but does not significantly alter voice pitch.

Transfeminine hormone therapy will cause breast growth, fat redistribution to a female pattern, and reduced body/facial hair growth. It will NOT significantly lower your voice pitch. If voice pitch change is a priority, you will likely need voice training or surgery in addition to hormones. Breast development varies, with many reaching a plateau at a smaller cup size (AAA or less) within 6 months.

Brown adipose tissue (BAT) glucose uptake during cold exposure does not significantly contribute to systemic glucose clearance or thermogenesis because most taken-up glucose is metabolized into lactate or used for glyceroneogenesis rather than mitochondrial oxidation.

Cold exposure activates brown fat, but don't expect it to significantly lower your blood sugar or burn calories through glucose oxidation. The glucose taken up is mostly recycled into lactate or fat, not burned for heat. Focus on other mechanisms if targeting glucose metabolism.

Intracellular triglyceride (TG) lipolysis-derived fatty acids are the primary energy source for brown adipose tissue (BAT) thermogenesis upon cold activation, although circulating fatty acids can substitute if intracellular stores are unavailable.

Cold exposure triggers brown fat to burn stored fat inside the cells for heat. This is the main mechanism, though it can switch to blood fat if needed.

Weekly oral fecal microbiota transplantation (FMT) from lean donors does not significantly improve insulin sensitivity, body weight, or body composition in adults with obesity and mild-to-moderate insulin resistance over a 12-week period.

For adults with obesity and mild insulin resistance, receiving weekly oral FMT capsules from lean donors does not significantly improve insulin sensitivity, weight, or body composition over 12 weeks. While the treatment is safe and alters gut bacteria, it should not be expected to replace lifestyle interventions like diet and exercise for metabolic improvement.

FMT from lean donors successfully engrafts donor-specific bacteria in the majority of obese recipients, with effects persisting for at least 12 weeks, although the degree of engraftment varies significantly by donor.

FMT from lean donors can successfully introduce new bacteria into your gut, and these changes can last for months. However, this microbial change alone does not guarantee improvements in insulin sensitivity or weight loss.